Catalyst Wire Dossier Catalyst Wire Dossier

Etrumadenant

etrumadenant · Arcus Biosciences, Inc.
Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for Etrumadenant, covering 2024-05-24 to 2026-03-04. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma [Phase 2]

See pricing